Incyte Corporation


Eli Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients

Eli Lilly and Company announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults...

Cincinnati Children’s Investigator Idea May Lead to Answer to COVID-19 Deadly Cytokine Storm: Ruxolitinib

Cincinnati Children’s researchers initially developed a transgenic mouse to model HLH (hemophagocytic lymphohistiocytosis), a deadly childhood immune disease but as it now turns out this effort may end up saving lives during the COVID-19 pandemic. Cincinnati...

Pin It on Pinterest